An ultrasensitive test detects TDP-43 seeds in CSF to diagnose FTLD-TDP. At-home blood tests show promise for remote dementia triage, but primary care use of plasma biomarkers remains limited.
Two experimental ALS therapies showed promise in recent clinical developments. Interim Phase 1/2 data suggest the antisense oligonucleotide QRL-201 restores a critical nerve protein and may slow disease decline, with a Phase 3 trial planned for 2027. Meanwhile, the oral therapy neflamapimod has been selected for testing in the UK's EXPERTS-ALS platform study, with first results expected this spring.
CervoMed presents new MRI data showing neflamapimod may reduce basal forebrain atrophy in dementia with Lewy bodies and finalizes Phase 3 trial design. The drug has also been selected for a UK-funded ALS platform trial, with first dosing expected by end of 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07033481 |
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06987643 |
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06815965 |
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies |
COMPLETED | PHASE2 |
